Proof of Mechanism Study of an Oral Hedgehog Inhibitor (GDC-0449) in Patients With Resectable Pancreatic Ductal Adenocarcinoma in the Pre-operative Window Period.

Trial Profile

Proof of Mechanism Study of an Oral Hedgehog Inhibitor (GDC-0449) in Patients With Resectable Pancreatic Ductal Adenocarcinoma in the Pre-operative Window Period.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms HIPPoS
  • Most Recent Events

    • 27 Jan 2014 Actual end date August 2012, added as reported by ClinicalTrials.gov record.
    • 08 Sep 2012 Accrual to date is 15% according to United Kingdom Clinical Research Network record.
    • 01 Sep 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top